An FDA advisory panel voted this week to add six peptides to the drug compounding list, including compounds like kisspeptin and thymosin beta-4. The panel rejected emideltide. Shares of HIMS climbed overnight following the committee's endorsement of four peptides. Bachem shares held steady after the vote. A recent study indicated peptides may help treat antibiotic-resistant bacteria. Meanwhile, RFK Jr. advocated for broader availability to controversial peptides, calling for loosened oversight. The vote reflects a broader shift in how regulators view compounded peptide therapies, which have drawn steady interest from patients seeking alternatives to traditional drugs. Researchers say peptide treatments could alter approaches to resistant infections, though concerns about quality persist. The committee's endorsement of four peptides paves the way for more widespread prescribing, even as watchdogs warn of limited evidence. Industry analysts note that peptide-focused companies may see heightened investor attention following the panel's decision. The rejection of emideltide, meanwhile, highlights the FDA's cautious stance on certain peptide candidates.